Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): Tools to predict in vivo bioavailability from orally applied drug suspensions

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 78, Issue 3, 2011, Pages 522-530

  Muenster, Uwe ^a   Pelzetter, Christian ^a   Backensfeld, Thomas ^a   Ohm, Andreas ^a   Kuhlmann, Thomas ^a   Mueller, Hartwig ^a   Lustig, Klemens ^a   Keldenich, Jörg ^a   Greschat, Susanne ^a   Göller, Andreas H ^a   Gnoth, Mark Jean ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Absorption; Bioavailability; Development; Dissolution; Solubility

Indexed keywords

ACICLOVIR; ATENOLOL; CAFFEINE; CARBAMAZEPINE; CIMETIDINE; DIGOXIN; FLUINDOSTATIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IBUPROFEN; KETOPROFEN; LUCIFER YELLOW; METHOTREXATE; METOPROLOL; PHENAZONE; PRAZOSIN; PROPRANOLOL; RANITIDINE; SALAZOSULFAPYRIDINE; THEOPHYLLINE; VERAPAMIL;

ADULT; ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG SOLUTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NORMAL HUMAN; RAT; SUSPENSION; TABLET; THERMODYNAMICS;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MOUTH; PARTICLE SIZE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHYSICOCHEMICAL PHENOMENA; RATS; RATS, WISTAR; SOLUBILITY; SUSPENSIONS; YOUNG ADULT;

EID: 79960574228     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.01.023     Document Type: Article

References (42)

1. S. Venkatesh, and R.A. Lipper Role of the development scientist in compound lead selection and optimization J. Pharm. Sci. 89 2000 145 154 (Pubitemid 30120795)
2. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25 (Pubitemid 27046991)
3. W.N. Charman, C.J. Porter, S. Mithani, and J.B. Dressman Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH J. Pharm. Sci. 86 1997 269 282 (Pubitemid 27113759)
4. W.H. Moos, and G.D. Green Recent advances in the generation of molecular diversity Annu. Rep. Med. Chem. 28 1993 315 324 (Chapter 33)
5. D.V. Patel, and E.M. Gordon Applications of small molecule combinatorial chemistry to drug discovery Drug Discov. Today 1 1996 134 144 (Pubitemid 126402198)
6. P.R. Andrews, D.J. Craik, and J.L. Martin Functional group contributions to drug-receptor interactions J. Med. Chem. 27 1984 1648 1657 (Pubitemid 15177908)
7. D. Singhal, and W. Curatolo Drug polymorphism and dosage form design: a practical perspective Adv. Drug Deliv. Rev. 56 2004 335 347 (Pubitemid 38201429)
8. J.B. Dressman, and C. Reppas In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs J. Eur. Pharm. Sci. 11 Suppl. 2 2000 73 80
9. P. Gribbon, and A. Sewing High-throughput drug discovery: what can we expect from HTS? Drug Discov. Today 10 2005 17 22 (Pubitemid 40164815)
10. T. Vasconcelos, B. Sarmento, and P. Costa Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discov. Today 12 2007 1068 1075 (Pubitemid 350186132)
11. S. Talegaonkar, A. Azeem, F.J. Ahmad, R.K. Khar, S.A. Pathan, and Z.I. Khan Microemulsions: a novel approach to enhanced drug delivery Recent Pat. Drug Deliv. Formul. 2 2008 238 257
12. Tripos, St. Louis, MO, Biobyte Software ClogP/CRMTM.
13. P. Ertl, and B. Rohde Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem. 43 2000 3714 3717
14. J.C. Shelley, A. Cholleti, L.L. Frye, J.R. Greenwood, M.R. Timlin, and M. Uchimaya Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules J. Comput. Aided Mol. Des. 21 2007 681 691
15. B.D. Christie, B.A. Leland, and J.G. Nourse Structure searching in chemical databases by direct lookup methods J. Chem. Inf. Comput. Sci. 33 1993 545 547
16. OECD Guideline for the Testing of Chemicals, 107, adopted July 27 1995 (last accessed 10.08.10). < http://www.oecd.org/dataoecd/17/35/1948169. pdf>.
17. T.J. Looney, USP Apparatus 4 (Flow-Through Method), Primer Dissolution Technologies, November 1996, pp. 10-12.
18. F. Wunder, M.J. Gnoth, A. Geerts, D. Barufe, and A. Novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors Mol. Pharm. 6 2008 326 336
19. Guidance for Industry Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), August 2000.
20. C. Hilgendorf, H. Spahn-Langguth, C.G. Regardh, E. Lipka, G.L. Amidon, and P. Langguth Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport J. Pharm. Sci. 89 2000 63 75 (Pubitemid 30080155)
21. S. Yee In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth Pharm. Res. 14 1997 763 766 (Pubitemid 27281671)
22. K. Mandagere, T.N. Thompson, and K.K. Hwang Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates J. Med. Chem. 45 2002 304 311 (Pubitemid 34073449)
23. G. Corti, F. Maestrelli, M. Cirri, N. Zerrouk, and P. Mura Development and evaluation of an in vitro method for prediction of human drug absorption. II. Demonstration of the method suitability Eur. J. Pharm. Sci. 27 2006 354 362 (Pubitemid 43143261)
24. M. Yazdanian, K. Briggs, C. Jankowsky, and A. Hawi The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs Pharm. Res. 21 2004 293 299 (Pubitemid 38221975)
25. A. Corsini, T.A. Jacobson, and C.M. Ballantyne Fluvastatin: clinical and safety profile Drugs 64 2004 1305 1323 (Pubitemid 38916344)
26. L.S. Gan, P.H. Hsyu, J.F. Pritchard, and D. Thakker Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers Pharm. Res. 10 1993 1722 1725 (Pubitemid 24000355)
27. S. Yamashita, T. Furubayashi, M. Kataoka, T. Sakane, H. Sezaki, and H. Tokuda Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells Eur. J. Pharm. Sci. 10 2000 195 204 (Pubitemid 30190095)
28. J. Keldenich Measurement and prediction of oral absorption Chem. Biodivers. 6 2009 2000 2013
29. S. Willmann, W. Schmitt, J. Keldenich, J. Lippert, and J.B. Dressman A physiological model for the estimation of the fraction dose absorbed in humans J. Med. Chem. 47 2004 4022 4031 (Pubitemid 38970963)
30. T. Yamagata, H. Kusuhara, M. Morishita, K. Takayama, H. Benameur, and Y. Sugiyama Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients Drug Metab. Dispos. 35 2007 1142 1148 (Pubitemid 46956435)
31. J. Schulze, A. Sacher, T. Backensfeld, A. Reichel, P. Lienau, In vitro and in vivo evaluation of pharmaceutical excipients: interaction potential with biological barriers, 2005 AAPS Annual Meeting and Exposition, November 2005, Nashville (M1135).
32. B. Davies, and T. Morris Physicological parameters in laboratory animals and humans Pharm. Res. 10 1993 1093 1099
33. T.T. Kararli Comparison of the gastrointestinal anatomy, physiology and biochemistry of humans and commonly used laboratory animals Biopharm. Drug Dispos. 16 1995 351 380
34. W.L. Chiou, and A. Barve Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rat Pharm. Res. 15 1998 1792 1795 (Pubitemid 28524594)
35. E.J. Calabrese, Table 33.9, Principles of animal extrapolation, Lewis Publisher, Chelsea, MI, 1991.
36. U. Fagerholm Prediction of human pharmacokinetics-gastrointestinal absorption J. Pharm. Pharmacol. 59 2007 905 916
37. J.B. Dressman, G.L. Amidon, and G.L. Fleisher Absorption potential: estimating the fraction absorbed for orally administered drugs J. Pharm. Sci. 74 1985 588 589
38. D.-M. Oh, R.M. Curl, and G.L. Amidon Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model Pharm. Res. 10 1993 264 270 (Pubitemid 23041742)
39. N.A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A.S. Hussain, H.E. Junginger, S.A. Stavchansky, K.K. Midha, V.P. Shah, and G.L. Amidon Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 1 2004 5 96
40. D. Hörter, and J.B. Dressman Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract Adv. Drug Deliv. Rev. 46 2001 75 87
41. S. Balbach, and C. Korn Pharmaceutical evaluation of early development candidates; the 100 mg-approach Int. J. Pharm. 275 2004 1 12 (Pubitemid 38481515)
42. J.B. Dressman, K. Thelen, and E. Jantratid Towards quantitative prediction of oral drug absorption Clin. Pharmacokin. 47 2008 655 667